DCC promoter hypermethylation in esophageal squamous cell carcinoma

Deleted in Colorectal Cancer (DCC) is a putative tumor suppressor gene, whose loss has been implicated in colorectal tumorigenesis. Decreased or loss of DCC expression has been demonstrated in a number of human cancers, including esophageal cancer. In this study, we analyzed esophageal squamous cell carcinoma (ESCC) cell lines and primary ESCCs as well as normal esophageal tissues for DCC methylation by bisulfite sequencing, methylation‐specific PCR (MSP) and/or quantitative methylation‐specific PCR (qMSP). When a qMSP cut‐off value for positivity was set to 1.0, DCC methylation was detected in 10 of 12 ESCC cell lines tested, 74% of primary ESCCs (n = 70), 0% of corresponding normal esophageal tissues (n = 20) and 0% of normal esophagus from healthy individuals (n = 19). DCC expression was undetectable in the majority of ESCC cell lines, and treatment with the DNA methyltransferase inhibitor 5‐aza‐2′‐deoxycytidine reactivated gene expression. DCC overexpression suppressed colony formation in ESCC cell lines, suggesting that DCC may function as a tumor suppressor gene in the esophagus. However, DCC methylation was not associated with any clinical or pathologic parameters measured. We have demonstrated that DCC methylation is a frequent and cancer‐specific event in primary ESCCs, suggesting that DCC and associated pathways may represent a new diagnostical therapeutic target. © 2008 Wiley‐Liss, Inc.

[1]  A. Carvalho,et al.  Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. , 2006, Cancer research.

[2]  N. Matsubara,et al.  Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa , 2006, Gut.

[3]  Zhihua Liu,et al.  5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. , 2005, Cancer letters.

[4]  T. Sugimura,et al.  Identification of 20 genes aberrantly methylated in human breast cancers , 2005, International journal of cancer.

[5]  H. Arakawa,et al.  Netrin-1 and its receptors in tumorigenesis , 2004, Nature Reviews Cancer.

[6]  C. Croce,et al.  Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  S. Goodman,et al.  Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  O. Cussenot,et al.  Quantification of expression of netrins, slits and their receptors in human prostate tumors , 2003, International journal of cancer.

[9]  F. Sato,et al.  Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. , 2002, Cancer cell.

[10]  M. Toyota,et al.  Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  G. Jenkins,et al.  Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma , 2002, The British journal of surgery.

[12]  Kayo Nakamura,et al.  Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  M. Saegusa,et al.  Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival. , 2001, Journal of clinical pathology.

[14]  A. Nakao,et al.  Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  T. Godfrey,et al.  Correlation between dysplasia and mutations of six tumor suppressor genes in Barrett's esophagus. , 2001, The Annals of thoracic surgery.

[16]  T. Motoyama,et al.  Frequent loss of expression without sequence mutations of the DCC gene in primary gastric cancer , 2001, British Journal of Cancer.

[17]  D. Bredesen,et al.  The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Yokota,et al.  Mutation and expression of the DCC gene in human lung cancer. , 2000, Neoplasia.

[19]  M. Saegusa,et al.  Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression , 2000, British Journal of Cancer.

[20]  Shahrooz Rabizadeh,et al.  The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis , 1998, Nature.

[21]  R. Sutton,et al.  Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. , 1998, British Journal of Cancer.

[22]  J. Jass,et al.  Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer. , 1998, Journal of clinical pathology.

[23]  S. Hamilton,et al.  Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. , 1998, The American journal of pathology.

[24]  R. Weinberg,et al.  Phenotype of mice lacking functional Deleted in colorectal cancer (Dec) gene , 1997, Nature.

[25]  M. Masu,et al.  Deleted in Colorectal Cancer (DCC) Encodes a Netrin Receptor , 1996, Cell.

[26]  L. Hedrick,et al.  The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. , 1995, Oncogene.

[27]  J. Zhang,et al.  [Expression and loss of heterozygosity of DCC gene in human lung cancer]. , 1995, Zhonghua yi xue za zhi.

[28]  M. Inoue,et al.  Loss of expression and loss of heterozygosity in the DCC gene in neoplasms of the human female reproductive tract. , 1995, British Journal of Cancer.

[29]  V. Reuter,et al.  Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors. , 1994, Oncogene.

[30]  A. Wyllie,et al.  Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. , 1993, British Journal of Cancer.

[31]  Patricia L. Blount,et al.  Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. , 1992, Cancer research.

[32]  Kathleen R. Cho,et al.  Identification of a chromosome 18q gene that is altered in colorectal cancers. , 1990, Science.

[33]  D. Bredesen,et al.  The dependence receptor hypothesis , 2004, Apoptosis.

[34]  G. Yang,et al.  Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. , 1999, Carcinogenesis.